Table 1

Selected positive phase III studies in metastatic castrate-refractory prostate cancer

Agent	Method of action	Year of publication	Median survival benefit	Additional benefit
Docetaxel[9]	chemotherapy	2004	2.9 months	Improved QOL
Sipuleucel-T[12]	immunotherapy	2010	4.1 months	NA
Cabazitaxel[11]	chemotherapy	2010	2.4 months	NA
Abiraterone[13]	AR targeted	2011	4.6 months	Reduced pain
Enzalutamide[14]	AR targeted	2012	4.8 months	Improved QOL
Alpharadin[15]	radioisotope	2013*	3.6 months	Reduced pain

AR = androgen receptor; QOL= quality of life * not yet published in full but expected later in 2013